FDA
-
-
-
-
-
-
-
Aradigm Announces Results of Third Party Verification for Apulmiq (formerly Linhaliq)
-
-
-
-
-
-
-
Aradigm Announces Fourth Quarter 2017 and Full Year Financial Results
-
-
-
-
-
-
-
Aradigm Corp. (ARDM) Confirms FDA Advisory Committee Did Not Recommend Approval for Linhaliq
-
-
-
-
-
-
-
Aradigm (ARDM) Reports FDA Advisory Committee Meeting for Linhaliq
-
-
-
-
-
-
-
Aradigm (ARDM) PT Raised to $10 at Ladenburg Thalmann
-
-
-
-
-
-
-
Aradigm Corp. (ARDM) Submits NDA for U.S. Marketing Approval of Linhaliq in Non-Cystic Fibrosis Bronchiectasis
-
-
328,602 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

